BioTuesdays

Category - Markets

oncosec
Markets

Dawson James starts OncoSec Medical at buy; PT $10

Dawson James Securities launched coverage of OncoSec Medical (NASDAQ:ONCS) with a “buy” rating and $10 price target. The stock closed at $3.19 on July 24. OncoSec has developed a plasmid-based vector that is delivered...

July 27, 2020
Aravive Logo
Markets

HCW ups Aravive PT to $26 from $15

H.C. Wainwright raised its price target for Aravive (NASDAQ:ARAV) to $26 from $15 after the company announced successful completion of its Phase 1b trial testing AVB-500 in patients with platinum resistant ovarian...

July 23, 2020
89bio
Markets

BTIG starts 89bio at buy; PT $51

BTIG launched coverage of 89bio (NASDAQ:ETNB) with a “buy” rating and $51 price target. The stock closed at $33.14 on July 22. 89bio is developing BIO89-100, a stabilized fibroblast growth factor 21 (FGF21) analog, for...

July 23, 2020
Markets

Brookline starts MiRagen Therapeutics at buy; PT $6

Brookline Capital Markets initiated coverage of MiRagen Therapeutics (NASDAQ:MGEN) with a “buy” rating and 12-to-18 month price target of $6. The stock closed at $1.02 on July 20. MiRagen is working in hematologic...

July 21, 2020
Markets

BTIG starts Akouos at buy; PT $35

BTIG initiated coverage of Akouos (NASDAQ:AKUS) with a “buy” rating and $35 price target. The stock closed at $21.12 on July 20. Akouos is focused on the development of highly specific genetic medicines for hearing loss...

July 21, 2020
EyeGate Pharmaceuticals
Markets

AGP starts EyeGate Pharma at buy; PT $9.50

Alliance Global Partners launched coverage of EyeGate Pharmaceuticals (NASDAQ:EYEG) with a “buy” rating and price target of $9.50, representing a price-to-sales multiple of eight times based on 2022 revenue estimates...

July 21, 2020
Markets

Piper Sandler starts Zynex at OW; PT $30

Piper Sandler launched coverage of Zynex (NASDAQ:ZYXI) with an “overweight” rating and $30 price target. The stock closed at $21.42 on July 17. Zynex sells the only three-in-one, at home, chronic pain management product...

July 20, 2020
electroCore Logo
Markets

HCW ups electroCore PT to $2.50 from $1.50

H.C. Wainwright raised its price target for electroCore (NASDAQ:ECOR) to $2.50 from $1.50, citing the FDA’s emergency use authorization of gammaCore, the company’s lead product, to treat COVID-19 patients. The stock...

July 15, 2020
NextCure
Markets

BTIG slashes NextCure PT to $27 from $61

BTIG more than halved the price target for NextCure (NASDAQ:NXTC) to $27 from $61 after the company announced that its NC318 immunoncology antibody would not be moving forward into stage 2 of the Simon-2-stage trial in...

July 14, 2020